H. Lundbeck A/S- (OTCMKTS:HLUYY) – Stock analysts at Jefferies Group lowered their FY2021 earnings per share (EPS) estimates for H. Lundbeck A/S- in a research note issued to investors on Thursday. Jefferies Group analyst P. Welford now anticipates that the company will post earnings of $2.99 per share for the year, down from their prior estimate of $3.80.

Separately, Zacks Investment Research raised H. Lundbeck A/S- from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a report on Wednesday, November 15th.

H. Lundbeck A/S- (OTCMKTS HLUYY) traded down $0.06 during midday trading on Monday, hitting $51.73. The stock had a trading volume of 1,615 shares, compared to its average volume of 4,141. The firm has a market cap of $9,947.41, a P/E ratio of 26.83, a PEG ratio of 3.12 and a beta of 0.09. The company has a current ratio of 1.36, a quick ratio of 1.13 and a debt-to-equity ratio of 0.07. H. Lundbeck A/S- has a 12 month low of $40.70 and a 12 month high of $66.67.

TRADEMARK VIOLATION NOTICE: “H. Lundbeck A/S- Forecasted to Earn FY2021 Earnings of $2.99 Per Share (HLUYY)” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://theolympiareport.com/2018/02/13/h-lundbeck-a-s-forecasted-to-earn-fy2021-earnings-of-2-99-per-share-hluyy.html.

About H. Lundbeck A/S-

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.